US biotechs Acadia Pharma and Harmony Biosciences have both suffered setbacks in phase 3 trials of drugs for rare diseases – respectively Prader-Willi and Fragile X syndrome, and in one case at least, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback